KCNS3 encodes Kv9.3, an electrically silent potassium channel regulatory subunit that modulates delayed rectifier potassium channel activity by slowing deactivation and inactivation kinetics 1. Although incapable of forming functional channels independently, Kv9.3 assembles into heteromeric complexes with KCNB1 (Kv2.1), where it amplifies potassium current and shifts channel voltage dependence 12. Recent work demonstrates that Kv2/KvS heteromers containing KCNS3 predominate in dorsal root ganglion neurons and can be pharmacologically distinguished from Kv2-only channels using selective inhibitors 3. KCNS3 is selectively expressed in cortical parvalbumin-positive GABAergic interneurons, where Kv9.3 subunits are critical for fast-spiking properties and gamma-frequency oscillations 4. In schizophrenia, KCNS3 mRNA levels are 23–40% lower in prefrontal cortical parvalbumin neurons 5, and experimental reduction impairs interneuron firing fidelity and gamma synchronization 4. Additionally, KCNS3 polymorphisms are associated with airway hyperresponsiveness in asthma 6, and the gene appears as a differentially expressed candidate in esophageal squamous cell carcinoma 7. Clinically, potassium channel modulators including amifampridine, dalfampridine, and guanidine target pathways relevant to conditions affecting neuromuscular transmission. The role of KCNS3 in parvalbumin neuron dysfunction suggests potential therapeutic relevance in psychiatric and neurological disorders characterized by impaired cortical synchronization.